Replicor: leading the fight against hepatitis B and D

Over 80% of those who contract hepatitis B virus (HBV) recover from the disease, but some 350 million people worldwide are not able to control the virus and develop chronic infection that can seriously damage the liver — over 750,000 people die from complications every year.

Go to the profile of Replicor Inc.
Oct 25, 2016
1
0
Page of
Go to the profile of Replicor Inc.

Replicor Inc.

Replicor is a privately held biopharmaceutical company located in Montreal, Canada. Our novel nucleic acid polymer (NAP) technology has the unique ability to eliminate the viral surface antigen protein in patients with HBV and HDV infection, a key step in achieving functional cure in these patients. NAP-based combination therapy has produced the most advanced animal and human clinical data in the development of the cure for HBV and HDV infection. The company is dedicated to accelerating the development of an effective treatment for patients with HBV and HBV/HDV co-infection.

No comments yet.